Skip to main content
Erschienen in:

01.11.2009 | In der Diskussion: Komplementäre Onkologie

Sekundäre Pflanzenstoffe

verfasst von: Dr. J. Hübner, G. Spahn

Erschienen in: Die Onkologie | Ausgabe 11/2009

Einloggen, um Zugang zu erhalten

Zusammenfassung

Sekundäre Pflanzenstoffe haben gemäß präklinischen und epidemiologischen Daten interessante Eigenschaften bei der Prävention in der Onkologie. Während die Bedeutung einer gesunden Ernährung unbestritten ist, sind jedoch die epidemiologischen Daten für einzelne dieser Stoffe noch widersprüchlich. Prävention kann nicht auf einen einzelnen Pflanzenstoff oder eine Gruppe von einzelnen sekundären Pflanzenstoffen aufgebaut werden. Präklinisch liegen für alle diese Substanzen ebenfalls interessante Daten bezüglich ihrer direkten antitumoralen Wirkung vor. Sie weisen gleichzeitig aber auch auf das hohe Interaktionspotenzial hin und zeigen auch, dass die hochdosierte Einnahme von wirkungsvollen sekundären Pflanzenstoffen potenziell schädigende Wirkungen hat. Der Einsatz in Form von Nahrungsergänzungsmitteln außerhalb von klinischen Studien ist nicht empfehlenswert.
Literatur
1.
Zurück zum Zitat Sun CL et al (2006) Green tea, black tea and colorectal cancer risk. Carcinogenesis 27(7):1301–1309CrossRefPubMed Sun CL et al (2006) Green tea, black tea and colorectal cancer risk. Carcinogenesis 27(7):1301–1309CrossRefPubMed
2.
Zurück zum Zitat Myung SK et al (2008) Green tea consumption and risk of stomach cancer: A meta-analysis of epidemiologic studies. Int J Cancer Myung SK et al (2008) Green tea consumption and risk of stomach cancer: A meta-analysis of epidemiologic studies. Int J Cancer
3.
Zurück zum Zitat Seely D et al (2005) The Effect of Green tea consumption on Incidence of breast cancer and recurrence of breast cancer, a systematic Review and Meta-analysis. Integr Cancer Ther 4(2):144–155CrossRefPubMed Seely D et al (2005) The Effect of Green tea consumption on Incidence of breast cancer and recurrence of breast cancer, a systematic Review and Meta-analysis. Integr Cancer Ther 4(2):144–155CrossRefPubMed
4.
Zurück zum Zitat Kurahashi N et al (2008) Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 167(1):71–77CrossRefPubMed Kurahashi N et al (2008) Green tea consumption and prostate cancer risk in Japanese men: a prospective study. Am J Epidemiol 167(1):71–77CrossRefPubMed
5.
Zurück zum Zitat Song YJ et al (2008) Coffee, tea, colas, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17(3):712–716CrossRefPubMed Song YJ et al (2008) Coffee, tea, colas, and risk of epithelial ovarian cancer. Cancer Epidemiol Biomarkers Prev 17(3):712–716CrossRefPubMed
6.
Zurück zum Zitat Bettuzzi S et al (2006) Chemoprevention of human prostate cancer by oral administration of green tea atechins in volunteers with high-grade prostate intraepithelial neoplasia. Cancer Res 66(2):1234–1240CrossRefPubMed Bettuzzi S et al (2006) Chemoprevention of human prostate cancer by oral administration of green tea atechins in volunteers with high-grade prostate intraepithelial neoplasia. Cancer Res 66(2):1234–1240CrossRefPubMed
7.
Zurück zum Zitat Shimizu M et al (2005) EGCG inhibits activation of Her3 and expression of Cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 5(1):69–78PubMed Shimizu M et al (2005) EGCG inhibits activation of Her3 and expression of Cyclooxygenase-2 in human colon cancer cells. J Exp Ther Oncol 5(1):69–78PubMed
8.
Zurück zum Zitat Inoue M (2001) Regular consumption of green tea and the risk of brast cancer recurrence: Follow up-study form the Hospital-based Epidemiologic Research Program at Aiichi Cancer Center. Cancer Lett 167:175–182CrossRefPubMed Inoue M (2001) Regular consumption of green tea and the risk of brast cancer recurrence: Follow up-study form the Hospital-based Epidemiologic Research Program at Aiichi Cancer Center. Cancer Lett 167:175–182CrossRefPubMed
9.
Zurück zum Zitat Seely D et al (2005) The Effect of Green tea consumption on Incidence of breast cenacer and recurrence of breast cancer, a systematic Review and Meta-analysis. Integr Cancer Ther 4(2):144–155CrossRefPubMed Seely D et al (2005) The Effect of Green tea consumption on Incidence of breast cenacer and recurrence of breast cancer, a systematic Review and Meta-analysis. Integr Cancer Ther 4(2):144–155CrossRefPubMed
10.
Zurück zum Zitat Zhang M et al (2004) Green tea consumption enhances survival of epithelial ovarian cancer. Int J Cancer 112(3):465–469CrossRefPubMed Zhang M et al (2004) Green tea consumption enhances survival of epithelial ovarian cancer. Int J Cancer 112(3):465–469CrossRefPubMed
11.
Zurück zum Zitat Jatoi A et al (2003) A Phase II trial of green tea in the treatment of patients with androgen independent metastatic. Cancer 97(6):1442–1446CrossRefPubMed Jatoi A et al (2003) A Phase II trial of green tea in the treatment of patients with androgen independent metastatic. Cancer 97(6):1442–1446CrossRefPubMed
12.
Zurück zum Zitat Ward H et al (2008) Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the european prospective into cancer-norfolk-study. Cancer Epidemiol Biomarkers Prev 17(10):2891–2894CrossRefPubMed Ward H et al (2008) Lack of prospective associations between plasma and urinary phytoestrogens and risk of prostate or colorectal cancer in the european prospective into cancer-norfolk-study. Cancer Epidemiol Biomarkers Prev 17(10):2891–2894CrossRefPubMed
13.
Zurück zum Zitat Travis RC et al (2008) A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. Int J Cancer 122(3):705–710CrossRefPubMed Travis RC et al (2008) A prospective study of vegetarianism and isoflavone intake in relation to breast cancer risk in British women. Int J Cancer 122(3):705–710CrossRefPubMed
14.
Zurück zum Zitat Seo HS et al (2006) Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat Seo HS et al (2006) Stimulatory effect of genistein and apigenin on the growth of breast cancer cells correlates with their ability to activate ER alpha. Breast Cancer Res Treat
15.
Zurück zum Zitat Garcea G et al (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration Br J Cancer 90:1011–1015 Garcea G et al (2004) Detection of curcumin and its metabolites in hepatic tissue and portal blood of patients following oral administration Br J Cancer 90:1011–1015
16.
Zurück zum Zitat Garcea G et al (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients. Cancer Epidemiol Biomarkers Prev 14(1):120–125PubMed Garcea G et al (2005) Consumption of the putative chemopreventive agent curcumin by cancer patients. Cancer Epidemiol Biomarkers Prev 14(1):120–125PubMed
17.
Zurück zum Zitat Dhillon N et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14(14):4491–4499CrossRefPubMed Dhillon N et al (2008) Phase II trial of curcumin in patients with advanced pancreatic cancer. Clin Cancer Res 14(14):4491–4499CrossRefPubMed
18.
Zurück zum Zitat Epelbaum R et al (2008) Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 26 (May 20 suppl; abstr 15619) Epelbaum R et al (2008) Phase II study of curcumin and gemcitabine in patients with advanced pancreatic cancer. J Clin Oncol 26 (May 20 suppl; abstr 15619)
19.
Zurück zum Zitat Sakano K et al (2002) Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch Biochem Biophys 405(2):223–230CrossRefPubMed Sakano K et al (2002) Metal-mediated DNA damage induced by curcumin in the presence of human cytochrome P450 isozymes. Arch Biochem Biophys 405(2):223–230CrossRefPubMed
20.
Zurück zum Zitat Moy KA et al (2008) Urinary total isothiocyanates and colorectal cancer: a prospective study of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev 17(6):1354–1359CrossRefPubMed Moy KA et al (2008) Urinary total isothiocyanates and colorectal cancer: a prospective study of men in Shanghai, China. Cancer Epidemiol Biomarkers Prev 17(6):1354–1359CrossRefPubMed
21.
Zurück zum Zitat Tang L et al (2008) Consumption of raw cruciferous vegetables is inversly associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev 17(4):938–944CrossRefPubMed Tang L et al (2008) Consumption of raw cruciferous vegetables is inversly associated with bladder cancer risk. Cancer Epidemiol Biomarkers Prev 17(4):938–944CrossRefPubMed
22.
Zurück zum Zitat Peters U et al (2007) Serum lycopene other carotenoids and prostate cancer risk, a nested case-control study in the prostate, lung, colorectal and ovarian cancer screening trail. Cancer Epidemiol Biomarkers Prev 16(5):962–968CrossRefPubMed Peters U et al (2007) Serum lycopene other carotenoids and prostate cancer risk, a nested case-control study in the prostate, lung, colorectal and ovarian cancer screening trail. Cancer Epidemiol Biomarkers Prev 16(5):962–968CrossRefPubMed
23.
Zurück zum Zitat Boileau T et al (2003) Prostate carcinogenesis in N-methyl-N-nitrosourea (Nmu)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. JNCI J Natl Cancer Inst 95(21):1578–1586 Boileau T et al (2003) Prostate carcinogenesis in N-methyl-N-nitrosourea (Nmu)-testosterone-treated rats fed tomato powder, lycopene, or energy-restricted diets. JNCI J Natl Cancer Inst 95(21):1578–1586
24.
Zurück zum Zitat Kavanaugh CJ et al (2007) The U.S. Food and Drug Administration’s evidence-based review for qualified health claims. J Natl Cancer Inst 99(14):1074–1085CrossRefPubMed Kavanaugh CJ et al (2007) The U.S. Food and Drug Administration’s evidence-based review for qualified health claims. J Natl Cancer Inst 99(14):1074–1085CrossRefPubMed
25.
Zurück zum Zitat Voskuil DW et al (2008) Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. Nutr Cancer 60(3):342–353CrossRefPubMed Voskuil DW et al (2008) Effects of lycopene on the insulin-like growth factor (IGF) system in premenopausal breast cancer survivors and women at high familial breast cancer risk. Nutr Cancer 60(3):342–353CrossRefPubMed
26.
Zurück zum Zitat Bowen P et al (2002) Tomato sauce supplementation and prostate cancer: Lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 227:886–893 Bowen P et al (2002) Tomato sauce supplementation and prostate cancer: Lycopene accumulation and modulation of biomarkers of carcinogenesis. Exp Biol Med (Maywood) 227:886–893
27.
Zurück zum Zitat Clark PE et al (2006) Phase I-II prospective dose-escalation trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 67(6):1257–1261CrossRefPubMed Clark PE et al (2006) Phase I-II prospective dose-escalation trial of lycopene in patients with biochemical relapse of prostate cancer after definitive local therapy. Urology 67(6):1257–1261CrossRefPubMed
28.
Zurück zum Zitat Jatoi A et al (2007) A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer, results of a Phase II study from the North Central Cancer Treatment Group. Urology 69(2):289–294CrossRefPubMed Jatoi A et al (2007) A tomato-based, lycopene-containing intervention for androgen-independent prostate cancer, results of a Phase II study from the North Central Cancer Treatment Group. Urology 69(2):289–294CrossRefPubMed
29.
Zurück zum Zitat Schwenke C et al (2009) Lycopene for advanced hormone refractory prostate cancer: a prospective, open physe II pilot study. J Urol 181(3):1098–1103CrossRefPubMed Schwenke C et al (2009) Lycopene for advanced hormone refractory prostate cancer: a prospective, open physe II pilot study. J Urol 181(3):1098–1103CrossRefPubMed
30.
Zurück zum Zitat Boulton DW et al (1998) Extensive binding of the bioflavonoid quercetin tho human plasma protein. J Pharm Pharmacol 50:243–249PubMed Boulton DW et al (1998) Extensive binding of the bioflavonoid quercetin tho human plasma protein. J Pharm Pharmacol 50:243–249PubMed
31.
Zurück zum Zitat Lamson DW et al (2000) Antioxidants and Cancer III; Quercetin. Altern Med Rev 5(3):196PubMed Lamson DW et al (2000) Antioxidants and Cancer III; Quercetin. Altern Med Rev 5(3):196PubMed
32.
Zurück zum Zitat Cui Y et al (2008) Dietary flavonoid intake and lung cancer–a population-based case-control study. Cancer 112(10):2241–2248CrossRefPubMed Cui Y et al (2008) Dietary flavonoid intake and lung cancer–a population-based case-control study. Cancer 112(10):2241–2248CrossRefPubMed
33.
Zurück zum Zitat Ossola B et al (2008) Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Toxicology 250(1):1–8CrossRefPubMed Ossola B et al (2008) Time-dependent protective and harmful effects of quercetin on 6-OHDA-induced toxicity in neuronal SH-SY5Y cells. Toxicology 250(1):1–8CrossRefPubMed
34.
Zurück zum Zitat Duthie SJ et al (1997) The effect of dietary flavonoids on DNA damage (strand breaks and oxidised pyrimidines) and growth in human cells. Mutat Res 390:141–141PubMed Duthie SJ et al (1997) The effect of dietary flavonoids on DNA damage (strand breaks and oxidised pyrimidines) and growth in human cells. Mutat Res 390:141–141PubMed
35.
Zurück zum Zitat Liu FT et al (2008) Dietary flavonoids inhibit the anti-cancer effects of the proteasome inhibitor Bortezomib. Blood 112(9):3835–3846CrossRefPubMed Liu FT et al (2008) Dietary flavonoids inhibit the anti-cancer effects of the proteasome inhibitor Bortezomib. Blood 112(9):3835–3846CrossRefPubMed
36.
Zurück zum Zitat Boocock DJ et al (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of Resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16(6):1246–1252CrossRefPubMed Boocock DJ et al (2007) Phase I dose escalation pharmacokinetic study in healthy volunteers of Resveratrol, a potential cancer chemopreventive agent. Cancer Epidemiol Biomarkers Prev 16(6):1246–1252CrossRefPubMed
37.
Zurück zum Zitat Chan JY et al (2008) Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther 7(8) Chan JY et al (2008) Resveratrol displays converse dose-related effects on 5-fluorouracil-evoked colon cancer cell apoptosis: the roles of caspase-6 and p53. Cancer Biol Ther 7(8)
38.
Zurück zum Zitat Pearce VP et al (2008) Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene 27(17):2365–2374CrossRefPubMed Pearce VP et al (2008) Immortalization of epithelial progenitor cells mediated by resveratrol. Oncogene 27(17):2365–2374CrossRefPubMed
39.
Zurück zum Zitat Szende B et al (2000) Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 32(2):88–92PubMed Szende B et al (2000) Dose-dependent effect of resveratrol on proliferation and apoptosis in endothelial and tumor cell cultures. Exp Mol Med 32(2):88–92PubMed
40.
Zurück zum Zitat Ahmad KA et al (2003) Pro-oxidant activity of low doses of resveratrol inhibits hydrogen peroxide-induxed apoptosis. Ann N Y Acad Sci 1010:365–373CrossRefPubMed Ahmad KA et al (2003) Pro-oxidant activity of low doses of resveratrol inhibits hydrogen peroxide-induxed apoptosis. Ann N Y Acad Sci 1010:365–373CrossRefPubMed
41.
Zurück zum Zitat Wang TT et al (2008) Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis Wang TT et al (2008) Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis
42.
Zurück zum Zitat Laszczyk MN (2009) Pentacyclic triterpenes of the Lupane, Oleanane and Ursane Group as tools in cancer therapy. Planta Med (Epub ahead of print) Laszczyk MN (2009) Pentacyclic triterpenes of the Lupane, Oleanane and Ursane Group as tools in cancer therapy. Planta Med (Epub ahead of print)
43.
Zurück zum Zitat Jäger S, Laszczyk MN, Strüh CM et al (2008) Triterpenes from natural sources for parenteral and topical application. Planta Med 74:1119 Jäger S, Laszczyk MN, Strüh CM et al (2008) Triterpenes from natural sources for parenteral and topical application. Planta Med 74:1119
44.
Zurück zum Zitat Huyke C, Reuter J, Rödig M et al (2009) Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges 7:128–133PubMed Huyke C, Reuter J, Rödig M et al (2009) Treatment of actinic keratoses with a novel betulin-based oleogel. A prospective, randomized, comparative pilot study. J Dtsch Dermatol Ges 7:128–133PubMed
45.
Zurück zum Zitat Woelfle U, Laszczyk MN, Kraus M et al (2009) Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Invest Dermatol 2009, Aug 13 (Epub ahead of print) Woelfle U, Laszczyk MN, Kraus M et al (2009) Triterpenes promote keratinocyte differentiation in vitro, ex vivo and in vivo: a role for the transient receptor potential canonical (subtype) 6. J Invest Dermatol 2009, Aug 13 (Epub ahead of print)
46.
Zurück zum Zitat Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, Jansen B et al. (2000) Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 114:935–940CrossRefPubMed Selzer E, Pimentel E, Wacheck V, Schlegel W, Pehamberger H, Jansen B et al. (2000) Effects of betulinic acid alone and in combination with irradiation in human melanoma cells. J Invest Dermatol 114:935–940CrossRefPubMed
47.
Zurück zum Zitat Saleem M, Maddodi N, Abu Zaid M et al (2008) Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res 14:2119–2127CrossRefPubMed Saleem M, Maddodi N, Abu Zaid M et al (2008) Lupeol inhibits growth of highly aggressive human metastatic melanoma cells in vitro and in vivo by inducing apoptosis. Clin Cancer Res 14:2119–2127CrossRefPubMed
48.
Zurück zum Zitat Strüh C, Jäger S, Schempp CM et al (2008) Solubilized triterpenes from mistletoe show anti-tumor effects on skin-derived cell lines. Planta Med 74:1130CrossRef Strüh C, Jäger S, Schempp CM et al (2008) Solubilized triterpenes from mistletoe show anti-tumor effects on skin-derived cell lines. Planta Med 74:1130CrossRef
49.
Zurück zum Zitat Spahn G (2009) Eigene Anwendungsbeobachtung Spahn G (2009) Eigene Anwendungsbeobachtung
50.
Zurück zum Zitat Fulda S, Jeremias I, Steiner HH et al (1999) Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 82:435–441CrossRefPubMed Fulda S, Jeremias I, Steiner HH et al (1999) Betulinic acid: a new cytotoxic agent against malignant brain-tumor cells. Int J Cancer 82:435–441CrossRefPubMed
51.
Zurück zum Zitat Hostanska K, Daum G, Saller R (2002) Cytostatic and apoptosis-inducing activity of boswellic acids towards malignant cells in vitro. Anticancer Res 22:2853–2862PubMed Hostanska K, Daum G, Saller R (2002) Cytostatic and apoptosis-inducing activity of boswellic acids towards malignant cells in vitro. Anticancer Res 22:2853–2862PubMed
52.
53.
Zurück zum Zitat Flavin DF (2007) A lipoxygenase inhibitor in breast cancer brain metastases. J Neurooncol 82:91–93CrossRefPubMed Flavin DF (2007) A lipoxygenase inhibitor in breast cancer brain metastases. J Neurooncol 82:91–93CrossRefPubMed
54.
Zurück zum Zitat Spahn G (2007) Ex oriente lux: Weihrauch, Myrrhe, Ingwer und Opium in der onkologischen Palliativ- und Supportivmedizin. Phytotherapie 1:12–17 Spahn G (2007) Ex oriente lux: Weihrauch, Myrrhe, Ingwer und Opium in der onkologischen Palliativ- und Supportivmedizin. Phytotherapie 1:12–17
Metadaten
Titel
Sekundäre Pflanzenstoffe
verfasst von
Dr. J. Hübner
G. Spahn
Publikationsdatum
01.11.2009
Verlag
Springer-Verlag
Erschienen in
Die Onkologie / Ausgabe 11/2009
Print ISSN: 2731-7226
Elektronische ISSN: 2731-7234
DOI
https://doi.org/10.1007/s00761-009-1729-6

Weitere Artikel der Ausgabe 11/2009

Die Onkologie 11/2009 Zur Ausgabe

CME Weiterbildung · Zertifizierte Fortbildung

Nutzung von Tumorklassifikationen nach neoadjuvanter Therapie

Neu im Fachgebiet Onkologie

Informierte Frauen neigen zu späterem Mammografie-Screening

Frauen in ihren 40ern, die über die Vor- und Nachteile des Mammografie-Screenings auf Brustkrebs informiert werden, neigen stärker dazu, den Screeningbeginn nach hinten zu verschieben. Die Mehrheit aber nähme das Angebot an, wie eine US-Studie zeigt.

Endometriose-Subtypen und das Risiko für Ovarialkarzinome

19.07.2024 Ovarialkarzinom Nachrichten

US-Kohortendaten sprechen dafür, dass verschiedene Endometrioseformen unterschiedlich mit dem Risiko für Ovarialkarzinome assoziiert sind. Besonders erhöht ist das Risiko offenbar bei tief infiltrierenden und ovariellen Endometrioseformen.

Die zelluläre Differenzierung wird wiederhergestellt

18.07.2024 Akute myeloische Leukämie Nachrichten

Ivosidenib von Servier ist ein Inhibitor der mutierten Isoform der Isocitrat-Dehydrogenase-1 (IDH1) und wird zur Behandlung von Patientinnen und Patienten mit neu diagnostizierter akuter myeloischer Leukämie (AML) eingesetzt. Die Substanz sorgt für die Wiederherstellung der zellulären Differenzierung.

Weißer Hautkrebs: Ein Update zu Diagnostik und Therapie

18.07.2024 Fortbildungswoche 2024 Kongressbericht

In der aktualisierten Version der S3-Leitlinie „Aktinische Keratose und Plattenepithelkarzinom der Haut“ gibt es neue Empfehlungen, unter anderem zu erweiterten Optionen bei aktinischer Keratose sowie zur systemischen und chirurgischen Behandlung von Plattenepithelkarzinomen. Ein Überblick.

Update Onkologie

Bestellen Sie unseren Fach-Newsletter und bleiben Sie gut informiert.